Animal Pharm Interview - Vetco canine cancer drug begins to emerge as viable competitor with surgery



It has been two years since the launch of Antican® drug in Taiwan, the market response shows that Antican® begins to emerge as viable alternative to surgery when treating canine perianal gland tumors with its product features. Vetco had a chance to share some views with Animal Pharm, the global leading publication in animal health industry.

For more information about the published interview, please refer to the following URL: